Nalaganje...

Ubrogepant does not induce latent sensitization in a preclinical model of medication overuse headache

BACKGROUND: Ubrogepant, a small-molecule calcitonin gene-related peptide receptor antagonist, was recently approved as an oral medication for the acute treatment of migraine. This study aimed to determine whether ubrogepant shows efficacy in a preclinical model of migraine-like pain and whether repe...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Cephalalgia
Main Authors: Navratilova, Edita, Behravesh, Sasan, Oyarzo, Janice, Dodick, David W, Banerjee, Pradeep, Porreca, Frank
Format: Artigo
Jezik:Inglês
Izdano: SAGE Publications 2020
Teme:
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7412872/
https://ncbi.nlm.nih.gov/pubmed/32615788
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/0333102420938652
Oznake: Označite
Brez oznak, prvi označite!